Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Kreuznach – page 54

739 clinical trials in Bad Kreuznach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Kreuznach at a glance
739
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

739 trials in Bad Kreuznach

Open in trial search

Study on AZD2693 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis and PNPLA3 Genetic Marker

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD2693 sodium
  • Sponsor:AstraZeneca AB

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Safety and Tolerability of Teprotumumab for Patients with Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Phenylketonuria

Not recruiting

Study of pegvaliase injections compared to diet control in adolescents aged 12-17 with phenylketonuria (PKU)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Pegvaliase
  • Sponsor:Biomarin Pharmaceutical Inc.

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AC102
  • Sponsor:AudioCure Pharma GmbH

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Kreuznach

What the registry says about research in the country

01 Neonatal Care Research

Clinical trials focusing on improving oxygen administration in extremely preterm infants, investigating automated versus manual control systems to enhance respiratory support outcomes.

  • Respiratory Support Management
  • Oxygen Therapy Control
  • Premature Birth Complications

This innovative research aims to evaluate the effectiveness of closed-loop automatic control systems in preventing complications such as ROP, NEC, and BPD while monitoring long-term neurocognitive development in premature babies.

02 Pediatric Intensive Care

Studies examining advanced respiratory support technologies for infants born between 23 and 27 weeks of gestational age, with a focus on optimizing ventilation strategies.

  • Mechanical Ventilation
  • CPAP Management
  • Oxygen Therapy Safety

The research, supported by the German Federal Ministry for Education and Research, explores improvements in neonatal intensive care practices to enhance survival rates and reduce complications.

03 Long-term Developmental Outcomes

Investigation into the long-term effects of oxygen therapy management on neurocognitive development in premature infants, tracked over a 24-month period.

  • Developmental Assessment
  • Mortality Prevention
  • Quality of Life Improvement

This comprehensive study evaluates both immediate medical outcomes and extended developmental progress in extremely preterm infants receiving different oxygen administration methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.